Results from an early-phase clinical trial of a Chinese vaccine candidate, CoronaVac, revealed that the formulation appears safe and induces an antibody response in healthy volunteers aged 18 to 59......
Results from the first phase of the clinical trial of an Ebola vaccine based on the current strain of the virus suggests it is safe to use and provokes an immune response in recipients, Chinese......